Principles of Clinical Pharmacology

Arthur J. Atkinson Jr.,Darrell R. Abernethy,Charles E. Daniels,Robert Dedrick,Sanford P. Markey

• Publisher: Academic Press
• Year: 2011
• ISBN:
  9780080466422
• Edition: 2
• Topic: Medicine
• Subtopic: Pharmacology

This revised second edition covers the pharmacologic principles underlying the individualization of patient therapy and contemporary drug development, focusing on the fundamentals that underlie the clinical use and contemporary development of pharmaceuticals. Authors drawn from academia, the pharmaceutical industry and government agencies cover the spectrum of material, including pharmacokinetic practice questions, covered by the basic science section of the certifying examination offered by the American Board of Clinical Pharmacology. This unique reference is recommended by the Board as a study text and includes modules on drug discovery and development to assist students as well as practicing pharmacologists.

• Unique breadth of coverage ranging from drug discovery and development to individualization and quality assessment of drug therapy
• Unusual cohesive of presentation that stems from author participation in an ongoing popular NIH course
• Instructive linkage of pharmacokinetic theory and applications with provision of sample problems for self-study
• Wide-ranging perspective of authors drawn from the ranks of Federal agencies, academia and the pharmaceutical industry
• Expanded coverage of pharmacogenetics
• Expanded coverage of drug transporters and their role in interactions
• Inclusion of new material on enzyme induction mechanisms in chapters on drug metabolism and drug interactions
• A new chapter on drug discovery that focuses on oncologic agents
• Inclusion of therapeutic antibodies in chapter on biotechnology products

CHAPTER 1 Introduction to Clinical Pharmacology

ARTHUR J. ATKINSON, JR.

Clinical Center, National Institutes of Health, Bethesda, Maryland

Fortunately a surgeon who uses the wrong side of the scalpel cuts his own fingers and not the patient; if the same applied to drugs they would have been investigated very carefully a long time ago.

Rudolph Bucheim

Beitrage zur Arzneimittellehre, 1849 (1)

BACKGROUND

Clinical pharmacology can be defined as the study of drugs in humans. Clinical pharmacology often is contrasted with basic pharmacology. Yet applied is a more appropriate antonym for basic (2). In fact, many basic problems in pharmacology can only be studied in humans. This text will focus on the basic principles of clinical pharmacology. Selected applications will be used to illustrate these principles, but no attempt will be made to provide an exhaustive coverage of applied therapeutics. Other useful supplementary sources of information are listed at the end of this chapter.

Leake (3) has pointed out that pharmacology is a subject of ancient interest but is a relatively new science. Reidenberg (4) subsequently restated Leake’s listing of the fundamental problems with which the science of pharmacology is concerned:

1. The relationship between dose and biological effect.
2. The localization of the site of action of a drug.
3. The mechanism(s) of action of a drug.
4. The absorption, distribution, metabolism, and excretion of a drug.
5. The relationship between chemical structure and biological activity.

These authors agree that pharmacology could not evolve as a scientific discipline until modern chemistry provided the chemically pure pharmaceutical products that are needed to establish a quantitative relationship between drug dosage and biological effect.

Clinical pharmacology has been termed a bridging discipline because it combines elements of classical pharmacology with clinical medicine. The special competencies of individuals trained in clinical pharmacology have equipped them for productive careers in academia, the pharmaceutical industry, and governmental agencies, such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). Reidenberg (4) has pointed out that clinical pharmacologists are concerned both with the optimal use of existing medications and with the scientific study of drugs in humans. The latter area includes both evaluation of the safety and efficacy of currently available drugs and development of new and improved pharmacotherapy.

Optimizing Use of Existing Medicines

As the opening quote indicates, the concern of pharmacologists for the safe and effective use of medicine can be traced back at least to Rudolph Bucheim (1820–1879), who has been credited with establishing pharmacology as a laboratory-based discipline (1). In the United States, Harry Gold and Walter Modell began in the 1930s to provide the foundation for the modern discipline of clinical pharmacology (5). Their accomplishments include the invention of the double-blind design for clinical trials (6), the use of effect kinetics to measure the absolute bioavailability of digoxin and characterize the time course of its chronotropic effects (7), and the founding of Clinical Pharmacology and Therapeutics.

Few drugs have focused as much public attention on the problem of adverse drug reactions as did thalidomide, which was first linked in 1961 to catastrophic outbreaks of phocomelia by Lenz in Germany and McBride in Australia (8). Although thalidomide had not been approved at that time for use in the United States, this tragedy prompted passage in 1962 of the Harris–Kefauver Amendments to the Food, Drug, and Cosmetic Act. This act greatly expanded the scope of the FDA’s mandate to protect the public health. The thalidomide tragedy also provided the major impetus for developing a number of NIH-funded academic centers of excellence that have shaped contemporary clinical pharmacology in this country. These U.S. centers were founded by a generation of vigorous leaders, including Ken Melmon, Jan Koch-Weser, Lou Lasagna, John Oates, Leon Goldberg, Dan Azarnoff, Tom Gaffney, and Leigh Thompson. Collin Dollery and Folke Sjöqvist established similar programs in Europe. In response to the public mandate generated by the thalidomide catastrophe, these leaders quickly reached consensus on a number of theoretically preventable causes that contribute to the high incidence of adverse drug reactions (5). These causes include the following failures of approach:

1. Inappropriate polypharmacy.
2. Failure of prescribing physicians to establish and adhere to clear therapeutic goals.
3. Failure of medical personnel to attribute new symptoms or changes in laboratory test results to drug therapy.
4. Lack of priority given to the scientific study of adverse drug reaction mechanisms.
5. General ignorance of basic and applied pharmacology and therapeutic principles.

The important observations also were made that, unlike the teratogenic reactions caused by thalidomide, most adverse reactions encountered in clinical practice occurred with commonly used, rather than newly introduced, drugs, and were dose related, rather than idiosyncratic (9, 10).

Recognition of the considerable variation in response of patients treated with standard drug doses provided the impetus for the development of laboratory methods to measure drug concentrations in patient blood samples (10). The availability of these measurements also made it possible to apply pharmacokinetic principles to routine patient care. Despite these advances, serious adverse drug reactions (defined as those adverse drug reactions that require or prolong hospitalization, are permanently disabling, or result in death) have been estimated to occur in 6.7% of hospitalized patients (11). Although this figure has been disputed, the incidence of adverse drug reactions probably is still higher than is generally recognized (12). In addition, the majority of these adverse reactions continue to be caused by drugs that have been in clinical use for a substantial period of time (5).

The fact that most adverse drug reactions occur with commonly used drugs focuses attention on the last of the preventable causes of these reactions: the training that prescribing physicians receive in pharmacology and therapeutics. Bucheim’s comparison of surgery and medicine is particularly apt in this regard (5). Most U.S. medical schools provide their students with only a single course in pharmacology that traditionally is part of the second-year curriculum, when students lack the clinical background that is needed to support detailed instruction in therapeutics. In addition, Sjöqvist (13) has observed that most academic pharmacology departments have lost contact with drug development and pharmacotherapy. As a result, students and residents acquire most of their information about drug therapy in a haphazard manner from colleagues, supervisory house staff and attending physicians, pharmaceutical sales representatives, and whatever independent reading they happen to do on the subject. This unstructured process of learning pharmacotherapeutic technique stands in marked contrast to the rigorously supervised training that is an accepted part of surgical training, in which instantaneous feedback is provided whenever a retractor, let alone a scalpel, is held improperly.

Evaluation and Development of Medicines

Clinical pharmacologists have made noteworthy contributions to the evaluation of existing medicines and development of new drugs. In 1932, Paul Martini published a monograph entitled Methodology of Therapeutic Investigation that summarized his experience in scientific drug evaluation and probably entitles him to be considered the “first clinical pharmacologist” (14). Martini described the use of placebos, control groups, stratification, rating scales, and the “n of 1” trial design, and emphasized the need to estimate the adequacy of sample size and to establish baseline conditions before beginning a trial. He also introduced the term “clinical pharmacology.” Gold (6) and other academic clinical pharmacologists also have made important contributions to the design of clinical trials. More recently, Sheiner (15) outlined a number of improvements that continue to be needed in the use of statistical methods for drug evaluation, and asserted that clinicians must regain control over clinical trials in order to ensure that the important questions are being addressed.

Contemporary drug development is a complex process that is conventionally divided into preclinical research and development and a number of clinical development phases, as shown in Figure 1.1 for drugs licensed by the United States Food and Drug Administration (16). After a drug candidate is identified and put through in vitro screens and animal testing, an Investigational New Drug application (IND) is submitted to the FDA. When the IND is approved, Phase I clinical development begins with a limited number of studies in healthy volunteers or patients. The goal of these studies is to establish a range of tolerated doses and to characterize the drug candidate’s pharmacokinetic properties and initial toxicity profile. If these results warrant further development of the compound, short-term Phase II studies are conducted in a selected group of patients to obtain evidence of therapeutic efficacy and to explore patient therapeutic and toxic responses to several dose regimens. These dose-response relationships are used to design longer Phase III trials to confirm therapeutic efficacy and document safety in a larger patient population. The material obtained during preclinical and clinical development is then incorporated in a New Drug Application (NDA) that is submitted to the FDA for review. The FDA may request clarification of study results or further studies be...